UFH with heparin anti-Xa of 0.2–0.3 IU/mL or equivalent aPTT unless they had major bleeding. For patients with thrombosis at the initiation or during ECMO the targets were increased up to anti-Xa of 0.5–0.7 IU/mL or equivalent aPTT at local clinical discretion. Here, TNXA is linked to Venous thrombosis.